Developing Story
Teva v. Eli Lilly – CAFC Reversal of Headache Treatment Patent Invalidation (2026)
The Federal Circuit issued a precedential reversal of a district court's JMOL invalidating Teva's headache treatment patents under 35 U.S.C. § 112, distinguishing the facts from the Supreme Court's Amgen enablement decision. The ruling is significant for pharma patent litigation strategy and calibrates the post-Amgen written description and enablement standards.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Overview
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in *Teva Pharmaceuticals International GmbH v. Eli Lilly and Company*, reversing the District of Massachusetts's grant of judgment as a matter of law (JMOL) of invalidity of Teva's headache treatment patents (IPWatchdog, April 2026).
## Lower Court Ruling
The District of Massachusetts found that Teva's asserted claims were invalid for failing to satisfy both the **written description** and **enablement** requirements of 35 U.S.C. § 112. The district court granted JMOL of invalidity following trial.
## CAFC's Reversal
The Federal Circuit reversed, distinguishing the facts from its prior precedential decision in *Amgen Inc. v. Sanofi* — the landmark 2023 Supreme Court decision that tightened enablement standards for broad genus claims in the biologics context. The CAFC found the district court had misapplied the *Amgen* framework (IPWatchdog, April 2026).
## Legal Significance
**Distinguishing Amgen:**
- *Amgen* involved broadly claimed antibody genus claims requiring undue experimentation to practice across the full scope
- The Teva case apparently involved a different claim structure or specification disclosure that the CAFC found satisfied § 112 requirements under proper analysis
- This distinction is critical: post-*Amgen*, district courts have been aggressive in invalidating broad pharma/biotech claims; the CAFC is now calibrating the boundaries
**Implications for Patent Practitioners:**
- Establishes that *Amgen* does not categorically doom all broad pharma patent claims at trial
- JMOL of invalidity at the district court level on written description/enablement grounds remains reversible where the trial record supports the patentee
- May encourage pharma patentees to take broader claims to trial rather than settling or narrowing pre-suit
**Headache/CGRP Treatment Market:**
- The patents at issue relate to headache treatments — likely in the CGRP antibody space where both Teva (Ajovy) and Eli Lilly (Emgality) compete
- The reversal protects Teva's market position against Lilly's invalidity challenge
## Key Procedural Posture
- Decision is **precedential** — binding on future CAFC panels
- Case returns to district court; further proceedings expected